General Chemistry. Thin layer chromatography was carried out using Merck 60 F254 silica gel plates using appropriate solvent mixtures. Solvents were ACS reagent grade and anhydrous solvents (Aldrich and Acros) were used as received. Medium pressure chromatography was carried out using Biotage Isolera with Silicycle HP cartridges for compound purification. LCMS was performed using an Agilent 1100 HPLC system equipped with a Waters XTerra MS C18 5 m, 4.6 Å~ 50 mm column or Poroshell 120 EC-C18 4.6x100 mm column using an Agilent photodiode array detector and an in-line Agilent 6130 single quadrupole mass spectrometer. Analytical HPLC method involved gradient elution from 0 to 95% acetonitrile in water (0.1% formic acid) over 6 min. Agilent ChemStation software was used to develop methods. Final purity of the compounds was determined by 1 H-NMR or by analyzing chromatogram of the products at 210, 254 and 280 nm. All compounds reported were >95% pure as judged by HPLC.
The precipitate 189 mg (1.0 mmol) was dissolved in DMF (1.0 mL), the suspension cooled to 0 °C, whereupon phosphorus oxyhalide (POCl3) (3.0 mmol, 0.283 ml) was added dropwise. The light gray colored suspension was then stirred at room temp overnight. Ice-cold water (4 mL) was added, and the precipitate was filtered and dried under a vacuum to yield the corresponding aldehyde as a pure product (193 mg, 0.93 mmol, 93%). 1 
Preparation of ethyl 3-(4-acetamidophenyl)-3-oxopropanoate (11).
Ethyl (4-nitrophenyl)-3-oxopropanoate (273 mg, 1.16 mmol) was dissolved in 5 mL EtOH and subsequently treated with acetic acid (2 mL), HCl (2M, 1 mL) and 0.30 g iron power (-70 mesh).
The mixture was refluxed for 2 h where upon the cooled down, filtered through Celite and concentrated under evacuo. The resultant solid was taken up in methylene chloride, washed with water (x2), dried over Na2SO4 and concentrated to afford ethyl 3-(4-aminophenyl)-3oxopropanoate product which was forwarded to the next step without futher purification. LRMS m/z = 208.1 (M+H) + .
Ethyl 3-(4-aminophenyl)-3-oxopropanoate (0.8 mmol) was dissolved in 4 mL of methylene chloride and treated with Et3N (0.33 mL, 2.4 mmol) and neat acetyl chloride (1.0 mmol, 0.08 mL) and the solution was stirred at rt for 3 h. The reaction was quenched by addition of water and organic layer was separated. Aqueous layer was extracted with EtOAc (x2), combined organics dried over Na2SO4 and reduced to dryness to afford ethyl 3-(4-acetamidophenyl)-3-oxopropanoate (196mg, 99%). LRMS m/z = 250.0 (M+H) + .
Representative Procedure (II) for Preparation of Substituted 2-Benzoyl-3H-benzo-
[f]chromen-3-ones (13).
8-Bromo-2-(3-bromobenzoyl)-3H-benzo[f]chromen-3-one (13a)
To a solution of substituted 6-bromo-2-hydroxyl naphthaldehyde (124 mg, 0.5 mmol) in ethanol (5 mL) was added the corresponding ethyl-(3-bromophenyl)-3-oxopropanoate 95.5 µL (0.5 mmol). Piperidine (5 drops) was next added, and the reaction was heated under reflux for 2 h whereupon the reaction was allowed to cool down. The yellowish precipitate obtained was collected by filtration and washed with ethanol several times to get the condensation product 8- 
8-Bromo-2-(4-methylbenzoyl)-3H-benzo[f]chromen-3-one (13b)
819 mg (2.09 mmol, 58%). 1 
8-Bromo-2-benzoyl-3H-benzo[f]chromen-3-one (13e)
982 mg (2.6 mmol, 77%). 1 
8-Bromo-2-(4-chlorobenzoyl)-3H-benzo[f]chromen-3-one (13f)
284 mg (0.69 mmol, 69%). 1 
8-Bromo-2-(4-fluorobenzoyl)-3H-benzo[f]chromen-3-one (13k)
400 mg (1.01 mmol, 67%). 1 
8-bromo-2-(pyridine-4-carbonyl)benzo[f]chromen-3-one (13l)
90 mg (0.24 mmol, 16%). 1 N-(4-{8-bromo-3-oxobenzo[f]chromene-2-carbonyl}phenyl)acetamide (13n) 114 mg (0.26 mmol, 33%). LRMS: m/z 436.0 (M+H) + .
8-bromo-2-(pyridine-3-carbonyl)benzo[f]chromen-3-one (13m)

2-(3-bromobenzoyl)-3H-benzo[f]chromen-3-one (13o)
0.78 mg (2.06 mmol, 89%). 1 
8-methoxy 2-(3-bromobenzoyl)-3H-benzo[f]chromen-3-one (13p)
87.5 mg (0.21 mmol, 22%). 1 2H), 7.22 (d, J = 9.0, 1H), 5.35 (dd, J= 11.1, 6.9 Hz, 1H), 3.78 (ddd, J = 16.3, 11.1, 6.9 Hz, 2H). -2-(4-trifluoromethylbenzoyl)-1H,2H-naphtho[2,1-b]pyran-3-one (14f) 266 mg (0.60 mmol, 88%). 1 (ddd, J = 16. 8, 11 .4, 6.9 Hz, 2H).
8-Bromo
8-Bromo-2-(3-trifluoromethylbenzoyl)-1H,2H-naphtho[2,1-b]pyran-3-one (14g)
233 mg (0.52 mmol, 92%). 1 3.69 (ddd, J = 16.5, 11.7, 6.9 Hz, 2H).
8-Bromo-2-(4-bromobenzoyl)-1H,2H-naphtho[2,1-b]pyran-3-one (14h)
290 mg (0.63 mmol, 86%). 1 
